

Case Report

Corresponding author

Angela Daher, MD

PGY4

Department of Internal Medicine

Hotel Dieu de France Hospital

Beirut, Lebanon

E-mail: angela.daher@gmail.com

Volume 1 : Issue 1

Article Ref. #: 1000IMOJ1105

Article History

Received: March 19th, 2017

Accepted: March 31st, 2017

Published: April 3rd, 2017

Citation

Daher A, Haddad FG. Anarchic deposits: The intersection of calciphylaxis and hemochromatosis, A case report. *Intern Med Open J.* 2017; 1(1): 20-24. doi: [10.17140/IMOJ-1-105](https://doi.org/10.17140/IMOJ-1-105)

Copyright

©2017 Daher A. This is an open access article distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Anarchic Deposits: The Intersection of Calciphylaxis and Hemochromatosis, A Case Report

Angela Daher, MD^{1*}; Fady G. Haddad, MD²

¹PGY4, Department of Internal Medicine, Hotel Dieu de France Hospital, Beirut, Lebanon

²Associate Professor, Department of Internal Medicine, Hotel Dieu de France Hospital, Beirut, Lebanon

INTRODUCTION

Calciphylaxis is a rare disease occurring in usually obese women around the age of 40 years subject to hemodialysis. It can be prevented by controlling drug intake and biological markers. However, when installed it is irreversible and lethal. We report the case of a very young woman victim of non-observation with very deleterious consequence of calciphylaxis.

OBSERVATION

We report the case of a 26-year-old woman who was admitted to our hospital because of epistaxis and digital necrosis.

The patient was seen at our hospital 4 times since the age of 10. She had been diagnosed with Fanconi syndrome after a renal biopsy was done in 2001 for hypocalcemia, high PTH level and rachistism. Since then she had a hemodialysis 3 times a week. The patient reported many episodes of epistaxis, menorrhagia which were due to low platelets. Many investigations were done and a fibrotic medulla was diagnosed. Meanwhile, she received many platelet and red blood cells transfusions to recover from her severe anemia. Her last admission to this hospital was in February 2011 for severe hemorrhage after which she continued her medical treatment at a peripheral hospital.

Few months before her actual admission, the patient complained of a progressive dyspnea which was getting worse even on rest. She noted a loss of weight of 10 kg in 9 months and a loss of hearing with otorrhagia. She had as well digital necrosis with rapid progression and firm masses on both her right shoulder and right knee.

On presentation, the patient was very weak with inability to walk and active epistaxis. The distal parts of her 3rd and 4th fingers of her left hand as well as her 2nd, 3rd and 4th fingers of her right hand were necrotic and very painful (Figure 1). She had subcutaneous firm lesions with deformations of her upper limbs' articulations (Figure 2). She had a silver corneal arch with yellow corneal deposits (Figure 1). On auscultation she had normal vesicular murmur and normal cardiac sounds. Her pulses were very weak on both her upper and lower limbs. She had an hepatomegaly and a splenomegaly.

Her usual treatment was Moxonidine, Amlodipine, Ursodeoxycholic acid, Sevelamer, Alfacalcidol, Rabeprazole, Prednisolone, Erythropoetin, Naftidrofuryl, Sulodexide, Aspirine and weekly ferrous IV injections.

At first, we had to manage the epistaxis. The otolaryngology team described an anterior septal necrosis without evidence of telangiectasia and a chronic medial otitis which were the cause of the otorrhagia and epistaxis. A bilateral hemostatic packing with absorbable gela-



tin foam was done and the bleeding stopped 2 days later. The hypothesis of vasculitis was considered. A total body scan was done without evidence of pulmonary vasculitis or adenopathies. The immune assay was negative as well as the purified protein derivative (PPD) skin test (Table 1). A bone marrow biopsy was done to rule out any malignancy in cause of the low platelets; it came back positive for iron deposits and fibrinous changes.

Concerning the digital necrosis, we first did radiography of the hands which showed calcified vessels and calcified subcutaneous lesions (Figure 3).

The arterial doppler of both the upper and the lower limbs showed an occlusion of the left radial artery, weak blood flow at the right cubital artery and bilateral distal arteriopathy in the lower limbs. She received daily doses of Prostavasine with small improvement and decrease of the pain. However, 2 days later she complained of pain again with progression of the digital lesions. The hypothesis of calciphylaxis was considered as we had ischemic lesions with arterial occlusion without signs of vasculitis and subcutaneous calcified lesions. Moreover an echography of her right knee was done and showed an intra-articular echogenic calcific sediment linked to another superficial

sediment over the distal quadriceps. A fluid puncture was performed and got back sterile (Figure 4).

Her lab results were accurate with a secondary hyperparathyroidism with a high phosphocalcic product ($5,95 \text{ mmol}^2/\text{L}^2$) (Table 1). The Alfacalcidol was stopped and the Cinacalcet started.

One week after her admission the patient was still unable to walk and was getting weaker. A cardiac ultrasound was then performed. A hypertrophic cardiomyopathy with suspicion of amyloid deposits and a severe diastolic dysfunction were found. An optimal cardiac treatment was impossible due to its side effects which involved more vasoconstriction. A salivary gland biopsy was performed to provide evidence for any amyloid deposits. It came back negative for amyloidosis but with signs of iron deposits. The hypothesis of secondary hemochromatosis was more evident as the results were out. We suggested a cardiac MRI and a hepatic MRI to rule it in; the cardiac MRI was negative for iron deposits but with some imaging limitations (Figure 6) while the hepatic MRI came back positive for iron sediments (Figure 5). We initiated the Deferasirox (Exjade) at that time.




Table 1: Laboratory Results.

Variable	Reference range, adults	Jan-15	June 2016, before admission	First admission	Second admission
Hematocrit (%)	36-46	35.50	32.50	38.90	36.50
Hemoglobin (g/dl)	12.0-16.0	11.90	10.30	13.20	12.00
White-cell count (per mm ³)	4500-11000	7000.00	8100.00	9400.00	6700.00
Differential count (%)					
Neutrophils	40-70	68.00	77.00	79.00	75.00
Lymphocytes	22-44	19.00	16.00	15.00	17.00
Monocytes	4.0-11.0	12.00	6.00	5.00	
Eosinophils	0-8	1.00	1.00	1.00	
Basophils	0-3	0.00	0.00	0.00	
Platelet count (per mm ³)	150000-400000	33000.00	25000.00	40000.00	40000.00
Mean corpuscular volume (um ³)	80-100	94	97	90	
Erythrocyte count (per mm ³)	4000000-5200000	3770000	3360000	4320000	
Erythrocyte sedimentation rate (mm/hr)	0-20			31	
Sodium (mmol/liter)	135-145	141	138	138	139
Potassium (mmol/liter)	3.4-4.8	3.61	3.62	3.5	3.6
Chloride (mmol/liter)	100-108	93	98	97	
Carbon dioxide (mmol/liter)	23-31.9	27	18	19	16
Glucose (mg/dl)	70-110			113.5	
Albumin (g/dl)	3.3-5.0			31	
Calcium (mg/dl)	8.6-10.8		11.86	12	11.4
Phosphore (mg/dl)	2.5-4.5		5.8	5.9	5.4
Urea nitrogen (mg/dl)	8.0-25.0	46.4	46	67	30.5
Creatinine (mg/dl)	0.60-1.50	2.49		6.1	3.1
Alkaline phosphatase (U/liter)	30-100		246	329	489
Aspartate aminotransferase (U/liter)	9.0-32.0	26		31	41
alanine aminotransferase (U/liter)	7.0-30.0	34	20	35	48
Lactate dehydrogenase (U/liter)	110-210				
C-reactive protein (mg/liter)	<8	73.6		22.6	103
Ferritine (ng/ml)	12-150			4720	
Transferrin (mg/dl)	200-350			176	
Total serum iron (ug/dL)	30-170			70.4	
Transferrin saturation (%)	20-50			33.2	
Anti-thrombine III (%)				95	
Lupus-like anticoagulant				(-)	
Proteine C (%)	70-130			120	
Proteine S (%)	55-140			93	
Prothrombin time (sec)	11.0-14.0	14		13.9	
aPTT (sec)	20-40	26		32	
Anti-B2 glycoprotein				(-)	
Ag HBs				(-)	
ANA				(-)	
C3 (mg/100ml)	90-180			122	
C4 (mg/100ml)	10.0-40.0			35.4	
DsDNA				(-)	
Ac HBc				(-)	
Ac HBs				(-)	
Ac HCV				(-)	
Ac HIV				(-)	
p-ANCA				(-)	
c-aNCA				(-)	
TSH (mIU/l)	0.5-5			4.6	
PTH (pg/ml)	<46			514	333
Vit D(25 OH) (ng/ml)	5.0-75			5.3	

Figure 5: Hepatic MRI T2*.





Figure 6: Cardiac MRI- The Mean T2* was 29.9±0.7 ms. It is Superior to the Reference Range of 20 ms set for Machines of 1.5 Tesla.



The patient left home with her new treatments and was denied any blood transfusion. She spent 2 weeks at home and came back with fever and severe weakness. On examination the digital necrosis were surrounded by areas of redness and purulent secretions. The subcutaneous nodules were less firm and some had decreased in size.

An amputation of her fingers previously suggested and rejected by her family was now the only choice. The culture was positive for *E.Coli ESBL* and *E.Cloacae*. Moreover her right knee was red, swollen and warm; another puncture was performed but the culture was sterile. She received 2 weeks of Ertapenem. During her hospital stay we decided to remove her parathyroid glands as the phosphocalcic product was still high even though she was taking the Cinacalcet. An incomplete parathyroidectomy was done because of anesthetic complications. The PTH level fell from 333 pg/ml to 121 pg/ml. Our patient left the hospital and came back one month later.

During this admission, the patient reported pain and severe weakness with insomnia and anorexia. She was given fluids and the parathyroidectomy was completed. She was in a severely depressive mood and decided to go back home as she was not getting any better.

She died 2 hours after she reached her home.

DISCUSSION

Our patient presented unfortunately both calciphylaxis and secondary hemochromatosis.

In fact, calciphylaxis, also called calcific uraemic arteriopathy, is a rare disease occurring mainly in hemodialysis patients. It is characterized by medial calcification of the small arteries and ischemia of the subcutaneous tissue, often leading to necrosis of subcutaneous fat and skin. It may not be as rare as it seems to be because we believe that the actual incidence is of 1% per year.¹ Consequently the search for risk factors for calciphylaxis is crucial to prevent irreversible lesions. Among the risk factors described in the International Journal of Dermatology in 2007 (Table 2) our patient had too much which confirms the hypothesis of iatrogenicity.

Moreover, this young patient had for many years ferrous injections plus transfusions which concluded to secondary hemochromatosis. One study in 1986 suggested the possibility of iron overload as a challenger for systemic calciphylaxis.²

Table 2: Risk Factors for Calciphylaxis.⁹

Medications	Patient factors	Biochemical
Corticosteroids	Renal failure	Hypoalbuminemia
Vitamin D	Female	Hypercalcemia
Calcium salts	Caucasian	hyperphosphatemia
Immunosuppressants	Local trauma	High serum alkaline phosphatase
Iron salts	Obesity	High plasma parathyroid hormone
Insulin injections	Diabetes mellitus	High serum Ca ²⁺ ×PO ₄ product
Calcium-based phosphate binders	Malnutrition	Protein C and S deficiency
	hypotension	Vitamin D excess

Despite intensive combined therapies, the prognosis of both calciphylaxis and secondary hemochromatosis remains poor especially in the presence of necrotic lesions.

Many studies have emphasized the crucial role of a multidisciplinary therapeutic approach focusing on the correction of the underlying abnormalities of the calcium and phosphorus plasma concentrations in prevention for irreversible necrotic lesions. In fact, parathyroidectomy as well as the use of calcimimetics are actually the most recommended therapies for calciphylaxis. Parathyroidectomy must be done when parathyroid hormone (PTH) is higher than 500 pg/ml and when the $\text{Ca}^{2+}\times\text{PO}_4$ product is refractory to drugs. However, in our patient it was of limited efficacy. Other therapies have been suggested including hyperbaric oxygen,³ intravenous sodium thiosulphat,⁴ steroids⁵ and bisphosphonates,⁶ but their efficacy is based on scant evidence. On the other hand, calcimimetics increase the sensitivity of the calcium-sensing receptor to calcium decreasing the parathyroid hormone as a consequence. One study reported a very good response to Cinacalcet in a patient with calciphylaxis and contraindication for parathyroidectomy,⁷ which was not the case in our patient. This observation may be due to the advanced lesions in our patient associated with complete irreversibility.

Secondary hemochromatosis remains difficult to treat as the best treatment is phlebotomy which cannot be done to severe anemic patients who are usually subject to this condition. Iron chelators offer different means of achieving a negative iron balance and tolerable iron concentrations in body tissues. Deferasirox (Exjade) was probably the best choice for our patient because of its excretion in the biliary tract and its oral intake once daily. Moreover, a study published in 2015 reported a significant improvement of iron metabolism in hemodialysis patients with iron overload and an acceptable frequency of adverse effects.⁸ Our patient had a good tolerance but she was consistently weak and we did not look for biological improvement of the transferrin saturation. We believe that iron deposits were difficult to remove in the context of severe weakness and calciphylaxis.

CONCLUSION

Our case describes the deleterious effects that some of our practice as doctors can induce. Prevention medicine is not only about vaccinations but also about considering side effects of drugs. Calciphylaxis remains an important diagnosis to consider in patients with renal failure, with the aim of prevention and early therapy to reduce the associated morbidity and mortality. The astute physician should focus on the prevention and reduction of predisposing factors in cohorts at risk. Secondary hemochromatosis is an important side effect of multiple transfusions and ferrous injection. Physicians must limit unneeded therapies.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

REFERENCES

1. Hafner J, Keusch G, Wahl C, Burg G. Calciphylaxis: A syndrome of skin necrosis and acral gangrene in chronic renal failure. *Vasa*. 1998; 27: 137-143. Web site. <http://europepmc.org/abstract/med/9747147>. Accessed March 18, 2017.
2. Rubinger D, Friedlaender MM, Silver J, Kopolovic Y, Czaczkes WJ, Popovtzer MM. Progressive vascular calcification with necrosis of extremities in hemodialysis patients: A possible role of iron overload. *Am J Kidney Dis*. 1986; 7(2): 125-129. doi: [10.1016/S0272-6386\(86\)80132-9](https://doi.org/10.1016/S0272-6386(86)80132-9)
3. Vassa N, Twardowski ZJ, Campbell J. Hyperbaric oxygen-therapy in calciphylaxis-induced skin necrosis in a peritoneal-dialysis patient. *Am J Kidney Dis*. 1994; 23: 878-881. doi: [10.1016/S0272-6386\(12\)80145-4](https://doi.org/10.1016/S0272-6386(12)80145-4)
4. Guerra G, Shah RC, Ross EA. Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous haemofiltration using low calcium replacement fluid: Case report. *Nephrol Dial Transplant*. 2005; 20: 1260-1262. doi: [10.1093/ndt/gfh825](https://doi.org/10.1093/ndt/gfh825)
5. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: Risk factors, outcome and therapy. *Kidney Int*. 2002; 61: 2210-2217. doi: [10.1046/j.1523-1755.2002.00375.x](https://doi.org/10.1046/j.1523-1755.2002.00375.x)
6. Monney P, Nguyen QV, Perroud H, Descombes E. Rapid improvement of calciphylaxis after intravenous pamidrona therapy in a patient with chronic renal failure. *Nephrol Dial Transplant*. 2004; 19: 2130-2132. doi: [10.1093/ndt/gfh305](https://doi.org/10.1093/ndt/gfh305)
7. Velasco N, MacGregor MS, Innes A, MacKay IG. Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy? *Nephrol Dial Transplant*. 2006; 21: 1999-2004. doi: [10.1093/ndt/gfl114](https://doi.org/10.1093/ndt/gfl114)
8. Chen CH, Shu KH, Yang Y. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload. *Hematology*. 2015; 20(5): 304-310. doi: [10.1179/1607845414Y.0000000199](https://doi.org/10.1179/1607845414Y.0000000199)
9. Guldbakke KK, Khachemoune A. Calciphylaxis. *Int J Dermatol*. 2007; 46: 231-238. doi: [10.1111/j.1365-4632.2007.03160.x](https://doi.org/10.1111/j.1365-4632.2007.03160.x)